The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times per day, but this could change to once daily or another frequency). Depending on the part of the study, participants may also receive another study medicine. * In the first part of the study, people with melanoma or other solid tumors may also receive encorafenib. Encorafenib comes as a capsule and is taken once per day. * In the second part of the study, people with melanoma or other cancers with abnormalities in a gene called "BRAF" will receive PF-07799544 with other study medicines (for example, PF-07799933). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times per day, but this could change to once daily or another frequency). Depending on the part of the study, participants may also receive another study medicine. * In the first part of the study, people with melanoma or other solid tumors may also receive encorafenib. Encorafenib comes as a capsule and is taken once per day. * In the second part of the study, people with melanoma or other cancers with abnormalities in a gene called "BRAF" will receive PF-07799544 with other study medicines (for example, PF-07799933). Participants may receive the study medicines for about 2 years. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
-
Highlands Oncology Group, PA, Fayetteville, Arkansas, United States, 72703
Highlands Oncology Group, Fayetteville, Arkansas, United States, 72703
Highlands Oncology Group, PA, Rogers, Arkansas, United States, 72758
Highlands Oncology Group, Rogers, Arkansas, United States, 72758
Highlands Oncology Group, PA, Springdale, Arkansas, United States, 72762
Highlands Oncology Group, Springdale, Arkansas, United States, 72762
Highlands Oncology, Springdale, Arkansas, United States, 72762
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa, Florida, United States, 33612
Moffitt Cancer Center, Tampa, Florida, United States, 33612
Moffitt McKinley Hospital, Tampa, Florida, United States, 33612
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
16 Years to
ALL
No
Pfizer,
Pfizer CT.gov Call Center, STUDY_DIRECTOR, Pfizer
2029-08-21